FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination
NCT ID: NCT05270967
Last Updated: 2022-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
129 participants
OBSERVATIONAL
2021-07-29
2022-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COvid iMaging With POSitron Emission Tomography
NCT05009563
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
NCT03429387
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
NCT02378337
Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT
NCT04519255
Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19
NCT04764721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
F-18 FDG PET/CT imaging
Oncological imaging
Pfizer/biontech mRNA vaccine
COVID-19 vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kocaeli University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Serkan Isgoren
associate professor of nuclear medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Serkan Isgoren, Ass prof
Role: STUDY_CHAIR
Kocaeli University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kocaeli University School of Medicine Dep. of Nuclear Medicine
Kocaeli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1854-1863. doi: 10.1007/s00259-021-05314-2. Epub 2021 Mar 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GOKAEK-2021/14.18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.